-
10921por Newton, R, Carpenter, L, Casabonne, D, Beral, V, Babiker, A, Darbyshire, J, Weller, I, Weiss, R, Kwan, A, Bourboulia, D, Munoz, F, Lagos, D, Boshoff, CEnlace del recurso
Publicado 2006
Enlace del recurso
Enlace del recurso
Texto -
10922
-
10923
-
10924por Baur, M, Schernhammer, E, Gneist, M, Sevelda, P, Speiser, P, Hudec, M, Dittrich, ChEnlace del recurso
Publicado 2005
Enlace del recurso
Enlace del recurso
Texto -
10925por Olopade, F A, Norman, A, Blake, P, Dearnaley, D P, Harrington, K J, Khoo, V, Tait, D, Hackett, C, Andreyev, H J NEnlace del recurso
Publicado 2005
Enlace del recurso
Enlace del recurso
Texto -
10926por Chauveinc, L, Buthaud, X, Falcou, M C, Mosseri, V, De la Rochefordière, A, Pierga, J Y, Girodet, J, Salmon, R JEnlace del recurso
Publicado 2003
Enlace del recurso
Enlace del recurso
Texto -
10927
-
10928por Yamaguchi, Y, Miyahara, E, Ohshita, A, Kawabuchi, Y, Ohta, K, Shimizu, K, Minami, K, Hihara, J, Sawamura, A, Toge, TEnlace del recurso
Publicado 2003
Enlace del recurso
Enlace del recurso
Texto -
10929por McCarty, M F, Takeda, A, Stoeltzing, O, Liu, W, Fan, F, Reinmuth, N, Akagi, M, Bucana, C, Mansfield, P F, Ryan, A, Ellis, L MEnlace del recurso
Publicado 2004
Enlace del recurso
Enlace del recurso
Texto -
10930
-
10931
-
10932por Proctor, M J, Talwar, D, Balmar, S M, O'Reilly, D S J, Foulis, A K, Horgan, P G, Morrison, D S, McMillan, D CEnlace del recurso
Publicado 2010
Enlace del recurso
Enlace del recurso
Texto -
10933por Cuzick, Jack, Sestak, Ivana, Pinder, Sarah E, Ellis, Ian O, Forsyth, Sharon, Bundred, Nigel J, Forbes, John F, Bishop, Hugh, Fentiman, Ian S, George, William D“…INTERPRETATION: This updated analysis confirms the long-term beneficial effect of radiotherapy and reports a benefit for tamoxifen in reducing local and contralateral new breast events for women with DCIS treated by complete local excision. FUNDING: Cancer Research UK and the Australian National Health and Medical Research Council.…”
Publicado 2010
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
10934por Osorio, A, Milne, R L, Alonso, R, Pita, G, Peterlongo, P, Teulé, A, Nathanson, K L, Domchek, S M, Rebbeck, T, Lasa, A, Konstantopoulou, I, Hogervorst, F B, Verhoef, S, van Dooren, M F, Jager, A, Ausems, M G E M, Aalfs, C M, van Asperen, C J, Vreeswijk, M, Waisfisz, Q, Van Roozendaal, C E, Ligtenberg, M J, Easton, D F, Peock, S, Cook, M, Oliver, C T, Frost, D, Curzon, B, Evans, D G, Lalloo, F, Eeles, R, Izatt, L, Davidson, R, Adlard, J, Eccles, D, Ong, K-r, Douglas, F, Downing, S, Brewer, C, Walker, L, Nevanlinna, H, Aittomäki, K, Couch, F J, Fredericksen, Z, Lindor, N M, Godwin, A, Isaacs, C, Caligo, M A, Loman, N, Jernström, H, Barbany-Bustinza, G, Liljegren, A, Ehrencrona, H, Stenmark-Askmalm, M, Feliubadaló, L, Manoukian, S, Peissel, B, Zaffaroni, D, Bonanni, B, Fortuzzi, S, Johannsson, O T, Chenevix-Trench, G, Chen, X-C, Beesley, J, Spurdle, A B, Sinilnikova, O M, Healey, S, McGuffog, L, Antoniou, A C, Brunet, J, Radice, P, Benítez, JEnlace del recurso
Publicado 2011
Enlace del recurso
Enlace del recurso
Texto -
10935por Maughan, Timothy S, Adams, Richard A, Smith, Christopher G, Meade, Angela M, Seymour, Matthew T, Wilson, Richard H, Idziaszczyk, Shelley, Harris, Rebecca, Fisher, David, Kenny, Sarah L, Kay, Edward, Mitchell, Jenna K, Madi, Ayman, Jasani, Bharat, James, Michelle D, Bridgewater, John, Kennedy, M John, Claes, Bart, Lambrechts, Diether, Kaplan, Richard, Cheadle, Jeremy P“…The use of cetuximab in combination with oxaliplatin and capecitabine in first-line chemotherapy in patients with widespread metastases cannot be recommended. FUNDING: Cancer Research UK, Cancer Research Wales, UK Medical Research Council, Merck KGgA.…”
Publicado 2011
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
10936por Lee, Siow Ming, Khan, Iftekhar, Upadhyay, Sunil, Lewanski, Conrad, Falk, Stephen, Skailes, Geraldine, Marshall, Ernie, Woll, Penella J, Hatton, Matthew, Lal, Rohit, Jones, Richard, Toy, Elizabeth, Chao, David, Middleton, Gary, Bulley, Sue, Ngai, Yenting, Rudd, Robin, Hackshaw, Allan, Boshoff, Chris“…Patients who develop a first-cycle rash should continue to receive erlotinib, whereas those who do not have a rash after 28 days should discontinue erlotinib, because of the possibility of decreased survival. FUNDING: Cancer Research UK, Roche.…”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
10937por Zsiros, József, Brugieres, Laurence, Brock, Penelope, Roebuck, Derek, Maibach, Rudolf, Zimmermann, Arthur, Childs, Margaret, Pariente, Daniele, Laithier, Veronique, Otte, Jean-Bernard, Branchereau, Sophie, Aronson, Daniel, Rangaswami, Arun, Ronghe, Milind, Casanova, Michela, Sullivan, Michael, Morland, Bruce, Czauderna, Piotr, Perilongo, Giorgio“…INTERPRETATION: The SIOPEL-4 treatment regimen is feasible and efficacious for complete remission at the end of treatment for patients with high-risk hepatoblastoma. FUNDING: Cancer Research UK and Cancer Research Switzerland/Oncosuisse.…”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
10938
-
10939por Symonds, R Paul, Gourley, Charlie, Davidson, Susan, Carty, Karen, McCartney, Elaine, Rai, Debbie, Banerjee, Susana, Jackson, David, Lord, Rosemary, McCormack, Mary, Hudson, Emma, Reed, Nicholas, Flubacher, Maxine, Jankowska, Petra, Powell, Melanie, Dive, Caroline, West, Catharine M L, Paul, James“…This finding was accompanied by an increase in toxic effects (mainly diarrhoea, hypertension, and febrile neutropenia). FUNDING: Cancer Research UK and AstraZeneca.…”
Publicado 2015
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
10940por Mulvenna, Paula, Nankivell, Matthew, Barton, Rachael, Faivre-Finn, Corinne, Wilson, Paula, McColl, Elaine, Moore, Barbara, Brisbane, Iona, Ardron, David, Holt, Tanya, Morgan, Sally, Lee, Caroline, Waite, Kathryn, Bayman, Neil, Pugh, Cheryl, Sydes, Benjamin, Stephens, Richard, Parmar, Mahesh K, Langley, Ruth E“…INTERPRETATION: Although the primary outcome measure result includes the prespecified non-inferiority margin, the combination of the small difference in QALYs and the absence of a difference in survival and quality of life between the two groups suggests that WBRT provides little additional clinically significant benefit for this patient group. FUNDING: Cancer Research UK, Medical Research Council Clinical Trials Unit at University College London, and the National Health and Medical Research Council in Australia.…”
Publicado 2016
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto